CT47A6: A Potential Drug Target and Biomarker for Cancer and Testis Antigens

Target Name: CT47A6

NCBI ID: G728062

CT47A6

CT47A6: A Potential Drug Target and Biomarker for Cancer and Testis Antigens

CT47A6 is a protein that is expressed in a variety of tissues, including the brain, spleen, and Peyer's patches of the intestine. It is also highly expressed in cancer cells and testes, making it an attractive drug target for cancer and testis antigens.

The protein is a member of the differentiation region of the T-cell receptor (TCR), which is a protein that is responsible for cell survival and growth. CT47A6 is a type of co-stimulatory molecule that can activate the TCR, allowing it to induce cell proliferation and differentiate into T cells.

In cancer, the TCR is often aberrantly activated, leading to the development of cancer cells. CT47A6 has been shown to play a role in the regulation of TCR signaling, and it is possible that it may be a drug target for cancer.

In testis, CT47A6 is highly expressed in testes and has been associated with the development of testicular cancer. It is also involved in the regulation of testicular stem cell proliferation and differentiation.

As a potential drug target, CT47A6 offers several advantages. Firstly, it is expressed in a variety of tissues and is not limited to a specific type of cancer or disease, making it a more versatile target. Secondly, it is involved in the regulation of TCR signaling, which is a well-established drug target for cancer.

In addition, CT47A6 has been shown to play a role in the development of both cancer and testicular disease, making it a potential biomarker for these conditions. This may be useful for the development of targeted therapies that specifically target CT47A6 and are less likely to affect other tissues.

The potential clinical applications of CT47A6 as a drug target are vast. In cancer, CT47A6 has been shown to be a potential therapeutic target by inhibiting TCR signaling. This can lead to the inhibition of cancer cell proliferation and the regression of cancer cells.

In testis, CT47A6 has been shown to be involved in the development of testicular cancer. By targeting CT47A6 with drugs, it may be possible to inhibit its role in testicular cancer and potentially treat this disease.

In conclusion, CT47A6 is a protein that is expressed in a variety of tissues and is highly expressed in cancer cells and testes. It is a potential drug target for cancer and testis antigens, and its potential clinical applications are vast. Further research is needed to fully understand its role in cancer and testis disease and to develop effective therapies that specifically target CT47A6.

Protein Name: Cancer/testis Antigen Family 47 Member A6

The "CT47A6 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CT47A6 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets